Karl Dane Wittrup

Karl Dane Wittrup began their work experience in 1999 as the C.P. Dubbs Professor at the Massachusetts Institute of Technology. During their time there, they held the role of Associate Director at the Koch Institute, where they led a team of researchers focused on advancing cancer research through the integration of biology and engineering.

In 2007, Wittrup co-founded Adimab, LLC and served as the Chair of the Scientific Advisory Board and the Office of the CSO. Adimab specializes in antibody discovery and optimization, providing partners with a platform for the rapid expansion of their biologics pipelines.

Karl Dane subsequently co-founded and became a member of the Scientific Advisory Boards for Immunitas Therapeutics in 2019, Ankyra Therapeutics in 2020, Cullinan Oncology in 2020, 76Bio, Inc. in 2021, Mersana Therapeutics in 2015, Dragonfly Therapeutics, Inc. in 2017, Werewolf Therapeutics in 2018, and Strand Therapeutics in 2019.

Overall, Wittrup has a diverse background in academia, biotech entrepreneurial ventures, and advisory roles in the pharmaceutical and biotechnology industries.

Karl Dane Wittrup began their education journey in 1980 at The University of New Mexico, where they pursued a Bachelor of Science degree in Chemical Engineering. Karl Dane completed their undergraduate studies in 1984. Following this, from 1984 to 1988, Wittrup enrolled at Caltech, where they obtained a Ph.D. in Chemical Engineering. Throughout their education, their focus remained in the field of Chemical Engineering.